Dole Announces its Promises, Bringing Interdependent Prosperity to People and the Planet
Dole Packaged Foods and Dole Asia Fresh, divisions of Dole Asia Holdings Pte. Ltd.. announced today “The Dole Promise,” which aims to increase access to sustainable nutrition, decrease food waste, plastics in packaging and carbon emissions and grow value for the company’s stakeholders, including farmers and shareholders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005347/en/
The Dole Promise, inspired by Japanese philosophy, Sampo Yoshi. (Graphic: Business Wire)
“The Dole Promise reflects the recognition that 'business as usual' is unacceptable in the face of a looming food crisis and the growing expectations of the next generation," said Pier Luigi Sigismondi, President of Dole Packaged Foods. “The impacts of the COVID-19 global pandemic could see 265 million additional people pushed to the brink of starvation by the end of this year,1 double the numbers of last year. At the same time, the challenges of climate change, resource waste and declining natural resources still must be addressed. We believe it is time for a change, and we are taking action where we can be most effective – within our own business.”
The promise draws on the spirit of ‘Sampo Yoshi,’ an 18th century Japanese philosophy that views the well-being of society and business as interdependent, and ensures the business is beneficial to the seller, to the buyer and to the community.
“The triple-win concept of ‘Sampo Yoshi’ has been part of Japanese culture for centuries, and is now at the heart of The Dole Promise as we play our part in helping to restore balance in the world by doubling down on our mission to put the health of the planet at the heart of everything we do,” said Richard Toman, President Dole Asia Fresh Division. “It’s a promise that Dole is making to do business differently, and to join forces with those who are equally committed to bringing back the goodness of the earth.”
The Dole Promise frames this philosophy to include:
Better for People:
- Access to sustainable nutrition for 1 billion people by 2025
- Moving towards zero processed sugar in all Dole products by 2025
Better for Planet:
- Moving towards zero fruit loss from Dole farms to markets by 2025
- Moving towards zero fossil-based plastic packaging by 2025
- Aiming for net zero carbon emissions in Dole operations by 2030
Better for all Stakeholders:
- Dole will continue to positively impact all farmers, communities and people working for Dole – through its commitment to equal opportunity, living wages, and an ever-increasing level of safety, nutrition, and wellbeing. The company also seeks to advance human rights within the direct operations and supply chains by building a culture of transparency and accountability. The company also aims for a 50% increase in the value of its business by 2025.
The growing problem of food inequality, which existed before the pandemic, has now reached crisis proportions and needs a collective effort to address. Dole’s commitment to increase access to sustainable nutrition will play a role, along with its effort to eliminate food waste.
“Our promise is not just about improving our world today,” said Sigismondi. "We have a responsibility to future generations to work towards a more equitable and sustainable future.”
The launch video, “Dear Leaders of the World,” gives voice to the concern of today’s youth about their generation’s future if something doesn’t change now.
“The next generation is right to question why we have left problems like climate change for so long. There are inter-generational repercussions. That is why we are increasing our efforts in key areas like reducing carbon emissions and working towards removing plastic packaging from our supply chain. Our promise puts the heart of the planet and people at the center of everything we do,” added Sigismondi.
Elevating the end-to-end value chain
Addressing the many gaps in access to good nutrition and reduction of waste cannot be done alone. Dole is partnering with Solidaridad; an international civil society organization with over fifty years of experience in creating fair and sustainable supply chains from producer to consumer across five continents. They are developing innovative solutions for healthy and sustainable food systems ensuring that farmers and workers have a living income, influence over their destiny, and can produce in balance with nature. Dole is also enlisting the help of Forum for the Future, an organisation that works in partnership with business, governments and civil society to accelerate the shift toward a sustainable future, Future Food Institute a center of excellence for food intelligence and the food innovation ecosystem and Rocana, a venture capital firm focused on clean and functional nutrition.
Later this year, Dole is launching the Sunshine for All™ Investment Fund to support additional strategic partnerships and strategic investments in these areas around the world. The US$2 million annual fund will work with innovators, start-ups and progressive partners to help deliver on the Dole Promise in key areas such as nutrition products, materiality, advisory and implementation of crucial practices to help achieve the ambitions that have been set.
Additionally, Dole is bringing these commitments inside their company walls, with employee programs that educate and encourage all Dole employees to live “The Dole Promise.”
Dole Asia Holdings Pte. Ltd.
Dole Asia Holdings Pte. Ltd., is a worldwide leader and innovator in the production and marketing of high-quality packaged fruit and healthy snacks. Dole Asia Holdings is also one of Asia's largest producers and marketers of high-quality fresh fruits and vegetables. For more information please visit dolesunshine.com or doleintlcsr.com. The Dole Promises are from the Dole Asia Holdings group of companies, and apply to their products, which can be seen at sunshineforall.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom